Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Avutometinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 16/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.44 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avutometinib SCHEMBL29358292 | 1.00 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29360048 | 1.00 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL29515377 | 1.00 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL963844 | 0.99 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL959675 | 0.99 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL963841 | 0.99 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| Avutometinib SCHEMBL959677 | 0.99 | MAP2K1 (0.98) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| SCHEMBL24876938 | 0.94 | MAP2K1 (0.89) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| SCHEMBL958779 | 0.93 | MAP2K1 (0.88) | MAP2K1RAF1CYP2C9BRAFMAP2K2 | |
| SCHEMBL959279 | 0.93 | MAP2K1 (0.86) | MAP2K1RAF1CYP2C9BRAFMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| EP-3702445-A2 | NOVEL MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-09-02 | — | — | EP | claimed |
| EP-3643777-A1 | NOVEL MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-04-29 | — | — | EP | claimed |
| US-10576106-B2 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2020-03-03 | — | — | US | claimed |
| US-20190247441-A1 | NOVEL MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS, INC. (KR) | 2019-08-15 | — | — | US | claimed |
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | claimed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | claimed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | claimed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | claimed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | claimed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | claimed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | claimed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | MAP2K1 1179/4885MAP2K2 990/4885RAF1 1656/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | MAP2K1 2217/4885MAP2K2 2209/4885RAF1 2086/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | MAP2K1 73/4885MAP2K2 74/4885RAF1 56/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | MAP2K1 3163/4885MAP2K2 2806/4885RAF1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.